Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
- PMID: 31610267
- DOI: 10.1016/j.canlet.2019.10.014
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Abstract
Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.
Keywords: Cell-free DNA (cfDNA); Circulating tumor DNA (ctDNA); Circulating tumor cells (CTC); Diagnosis; Ovarian cancer; Prognosis.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Clin Chem Lab Med. 2018. PMID: 28753534 Review.
-
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.Cancer Res Treat. 2020 Oct;52(4):1219-1228. doi: 10.4143/crt.2019.688. Epub 2020 May 6. Cancer Res Treat. 2020. PMID: 32599986 Free PMC article.
-
Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.Methods Mol Biol. 2019;1909:47-73. doi: 10.1007/978-1-4939-8973-7_4. Methods Mol Biol. 2019. PMID: 30580422
-
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.Oncotarget. 2016 Jul 26;7(30):48832-48841. doi: 10.18632/oncotarget.9453. Oncotarget. 2016. PMID: 27223063 Free PMC article. Review.
-
Liquid biopsy in ovarian cancer.Adv Clin Chem. 2020;97:13-71. doi: 10.1016/bs.acc.2020.01.001. Epub 2020 Feb 14. Adv Clin Chem. 2020. PMID: 32448432 Review.
Cited by
-
Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer.Biology (Basel). 2024 Jan 31;13(2):88. doi: 10.3390/biology13020088. Biology (Basel). 2024. PMID: 38392306 Free PMC article. Review.
-
An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.Cancer Inform. 2023 Feb 1;22:11769351221150772. doi: 10.1177/11769351221150772. eCollection 2023. Cancer Inform. 2023. PMID: 36762284 Free PMC article. Review.
-
Protein Panel of Serum-Derived Small Extracellular Vesicles for the Screening and Diagnosis of Epithelial Ovarian Cancer.Cancers (Basel). 2022 Jul 30;14(15):3719. doi: 10.3390/cancers14153719. Cancers (Basel). 2022. PMID: 35954383 Free PMC article.
-
Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges.Front Oncol. 2023 Sep 6;13:1227657. doi: 10.3389/fonc.2023.1227657. eCollection 2023. Front Oncol. 2023. PMID: 37746296 Free PMC article. Review.
-
Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis.Med Oncol. 2023 Aug 10;40(9):265. doi: 10.1007/s12032-023-02128-0. Med Oncol. 2023. PMID: 37561363 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
